Loren Data Corp.

'

 
 

COMMERCE BUSINESS DAILY ISSUE OF JULY 30,1999 PSA#2399

Centers for Disease Control and Prevention (CDC), Procurement & Grants Office, SECTION III, 2920 Brandywine Road, Mailstop K-70, Atlanta, GA 30341-4146

Q -- PERFORM SUSCEPTIBILITY TESTING FOR ANTIMICROBIALS SOL 1999Q00249 DUE 081399 POC Susan Lyle, Purchasing Agent, (770) 488-2632 The Centers for Disease Control and Prevention intends to procure the services of a vendor to process blood culture bottles and agar slants for bacteria, mycobacteria, and fungi, and to perform antimicrobial susceptibility testing of isolated pathogens against antimicrobials used in the United States and for the various antimicrobials used in Malawi and Vietnam but not in the United States. The following testing is required: (A) Analysis of bottles and slants: (1) 1,415 Myco F/Lytic bottles are to be analyzed for bacteria, mycobacteria and fungi; (2) 235 Myco-Chek bottles are to be worked-up for mycobacteria; (3) 235 Middlebrook 7H11 agar slants to be processed for mycobacterial growth; (4) 235 Inhibitory Mold Agar slats are to be processed for fungi growth; (5) 235 Isolator chocolate agar slants are to be processed for bacterial growth. (B) Frozen Isolates: (1) Identification of 390 bacteria isolated from three culture systems; (2) Antimicrobial susceptibility testing of these 390 bacterial isolates; (3) Identification of 39 yeast isolates from three culture systems; (4) antimicrobial susceptibility testing of 39 yeasts isolates; (5) Identification of 160 mycobacterial isolates by gene probes, biochemical tests and high performance liquid chromatography; (6) antimicrobial susceptibility testing of 160 mycobacterial isolates; (7) Restriction Fragment Length Polymorphism (RFLP) analysis of M. tuberculosis isolates (approx 140 isolates); (8) Serotyping of 150 Salmonella isolates. In order to perform the required services, a laboratory must be accredited by the College of American Pathologists, and must be a large-volume diagnostic/research facility with reference laboratory-level expertise in the isolation and identification of fungi and mycobacteria. Personnel must have ten or more years experience conducting comparative blood culture studies with documented publications of these studies in the peer-reviewed medical literature. In addition, the laboratory should have recent (over the past three years) experience conducting bloodstream infection studies in sub-Saharan Africa and Southeast Asia, and culturing blood from patients in these regions for unexpected and emerging bacteria, mycobacteria, and fungi. The laboratory must have approved Biosafety level III containment facilities (detailed in "Biosafety in Microbiology and Biomedical Laboratories" HHS Publication 93-8395) to safely handle unknown, often dangerous, emerging pathogens responsible for bloodstream infections. All interested parties are requested to submit a written request to be provided an RFQ package. A sole source procurement is anticipated. Requests must reflect the RFQ number, reflected in Item 9 above. Submit requests to Sue Lyle at the above address, Mailstop K70, or via e-mail at SIL2@cdc.gov, or by facsimile at 770-488-2670 or 2671. A Request for Quotations will be issued on approximately August 16, 1999. SIC 8071, 8069. Posted 07/28/99 (I-SN359940). (0209)

Loren Data Corp. http://www.ld.com (SYN# 0077 19990730\Q-0005.SOL)


Q - Medical Services Index Page